Natera CFO Defends CEO Change, Calls $6B Revenue Target a 'Way Station'
Read source articleWhat happened
Natera CFO Mike Brophy publicly defended the immediate transition to a new CEO while announcing a new long-term revenue target of $6 billion by 2029, framing it as a 'way station' rather than an endpoint. This target implies more than a doubling of revenue from the current annualized run-rate of approximately $2.8 billion, requiring sustained strong execution in the Signatera oncology franchise. The comments come after Q1 2026 results showed 39% revenue growth but a widening operating loss, as R&D and SG&A expenses outpaced revenue. The CEO switch adds executive transition risk, especially given the outgoing CEO's recent large insider sales. Overall, the news reinforces management's ambition but does not address the core investor concern regarding the pace of operating leverage improvement.
Implication
Investors should treat the $6 billion 2029 revenue target with skepticism because it is far beyond the visible planning horizon and relies on flawless execution amid rising competition in MRD testing. The immediate CEO transition introduces uncertainty about strategic continuity, although the CFO's defense suggests stability. The market is likely to focus on whether Q2 and Q3 2026 show a narrowing operating loss and stable gross margins, as those are the leading indicators of the operating leverage thesis. Failure to improve leverage could undermine confidence in the long-term target and pressure the stock, which already prices in significant growth. Conversely, evidence of opex discipline and continued MRD volume acceleration would validate the growth narrative and support a more constructive stance.
Thesis delta
The core WAIT thesis is unchanged: strong demand for Signatera is not yet translating into operating leverage. The CEO switch adds a layer of execution risk, though the CFO's comments suggest continuity. The $6 billion revenue target is ambitious but not actionable for near-term valuation and does not alter the key near-term catalysts of opex growth and Japan PMDA approval.
Confidence
Medium